Compare Biogen Inc (BIIB) vs Southern Copper Corp (SCCO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Southern Copper Corp — how do they compare? Biogen Inc trades at $196.12 (market cap $28.34B), while Southern Copper Corp trades at $181 (market cap $152.16B). The key difference: Southern Copper Corp is far larger — about 5.4× Biogen Inc's market cap, and Southern Copper Corp pays a 2.17% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | SCCO | |
|---|---|---|
Market Cap | $28.34B | $152.16B |
Sector | Health | Basic Materials |
52-Week High | $216.63 | $218.85 |
52-Week Low | $122.68 | $90.54 |
Enterprise Value | $30.62B | $154.22B |
Dividend Yield | — | 2.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
Southern Copper (SCCO) trades at $174.53, down 0.74% on the day, with a bearish technical signal and mixed analyst sentiment. The stock shows strong fundamentals, including a 32.3% net income margin and consistent earnings beats, with Q1 2026 EPS of $1.90 exceeding the $1.82 estimate. Revenue grew to $13.42 billion in 2025, and cash flow from operations reached $4.75 billion. Recent corporate actions include a $1.00 dividend and a 1:1.01 stock split effective May 13, 2026.
The outlook for SCCO is supported by robust profitability and growth in the copper sector, driven by AI and infrastructure demand, but risks include high valuation multiples and bearish technical indicators. Analyst consensus is cautious with a $151.58 price target below the current price, indicating potential downside despite strong operational performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Southern Copper Corp
Southern Copper Corp is an integrated producer of copper and other minerals and operates the mining, smelting, and refining facilities in Peru and Mexico. Its production includes copper, molybdenum, zinc, and silver. The company operates through the following segments: Peruvian operations, Mexican open-pit operations, and Mexican underground mining operations. Southern Copper generates the majority of its revenue from the sale of copper and the rest from the sale of non-copper products, such as molybdenum, silver, zinc, lead, and gold. Its geographical segments are The Americas, Europe, and Asia.
Read more on SCCO →
